Authors: | Panikar, S. S.; Shmuel, S.; Lewis, J. S.; Pereira, P. M. R. |
Article Title: | PET and optical imaging of caveolin-1 in gastric tumors |
Abstract: | Previous studies have suggested tumoral caveolin-1 (CAV1) as a predictive biomarker for the response to anti-HER2 antibody drug therapies in gastric tumors. In this study, radiolabeled and fluorescently labeled anti-CAV1 antibodies were developed and tested as an immunoPET or optical imaging agent to detect CAV1 in HER2-positive/CAV1-high NCIN87 gastric tumors. The expression of CAV1 receptors in NCIN87 gastric tumors and nontumor murine organs was determined by Western blot. Binding assays were performed to validate the anti-CAV1 antibody specificity for CAV1-expressing NCIN87 cancer cells. Subcutaneous and orthotopic NCIN87 xenografts were used for PET imaging and ex vivo biodistribution of the radioimmunoconjugate. Additional HER2-PET and CAV1-optical imaging was also performed to determine CAV1 in the HER2-positive tumors. Zr-89-labeled anti-CAV1 antibody was able to bind to CAV1-expressing NCIN87 cells with a B(max )value of 2.7 x 10(3) CAV1 receptors/cell in vitro. ImmunoPET images demonstrated the localization of the antibody in subcutaneous NCIN87 xenografts. In the orthotopic model, CAV1 expression was also observed by optical imaging in the HER2-positive tumors previously imaged with HER2-PET. Ex vivo biodistribution analysis further confirmed these imaging results. The preclinical data from this study demonstrate the potential of using CAV1-PET and optical imaging for detecting gastric tumors. |
Keywords: | down-regulation; carcinoma; breast-cancer; expression |
Journal Title: | ACS Omega |
Volume: | 8 |
Issue: | 39 |
ISSN: | 2470-1343 |
Publisher: | American Chemical Society |
Date Published: | 2023-10-03 |
Start Page: | 35884 |
End Page: | 35892 |
Language: | English |
ACCESSION: | WOS:001068500600001 |
DOI: | 10.1021/acsomega.3c03614 |
PROVIDER: | wos |
PMCID: | PMC10552508 |
PUBMED: | 37810678 |
Notes: | Article -- Source: Wos |